Sensorion Announces Positive Data Safety Monitoring Board Review of Phase 2 trial for SENS-401 in Sudden Sensorineural Hearing Loss. Read

Sensorion announces €5.6m non-dilutive funding to support SENS-401 Phase 2 study in Sudden Sensorineural Hearing Loss. French ministry of armed forces to participate in the study. Read

Sensorion announces results from SENS-111 Phase 2b trial in acute unilateral vestibulopathy. pdfread

Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover. pdfRead

Sensorion reports its 2019 first half results - Signature of a framework agreement with Institut Pasteur in gene therapy - Financial position strengthened with the issuance of a €20m mandatory convertible bond. pdfRead


20200910 pipeline


Patient center

Corporate presentation